Kite

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Phase 3, Recruiting, 2026, 550 people, 18 Mar 2026, clinicaltrials.gov

NCT07304154

Phase 1, Recruiting, 2026, 52 people, 26 Dec 2025, clinicaltrials.gov

NCT06413498

Phase 3, Active, not recruiting, 2024, 452 people, 14 May 2024, clinicaltrials.gov

NCT06079164

Phase 1, Active, not recruiting, 2023, 21 people, 12 Oct 2023, clinicaltrials.gov

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Collaborator, Phase 1, Active, not recruiting, 2023, 8 people, 15 Aug 2023, clinicaltrials.gov

NCT05605899

Phase 3, Active, not recruiting, 2023, 300 people, 4 Nov 2022, clinicaltrials.gov

NCT05495464

Collaborator, Early phase 1, Active, not recruiting, 2022, 22 people, 10 Aug 2022, clinicaltrials.gov

NCT05459571

Phase 2, Completed, 2022, 35 people, 15 Jul 2022, clinicaltrials.gov

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

Phase 1, Active, not recruiting, 2022, 24 people, 13 Jul 2022, clinicaltrials.gov

NCT05371093

Phase 3, Active, not recruiting, 2022, 231 people, 12 May 2022, clinicaltrials.gov

NCT05108805

Collaborator, Phase 4, Completed, 2021, 25 people, 5 Nov 2021, clinicaltrials.gov

NCT04789408

Phase 1, Terminated, 2021, 15 people, 9 Mar 2021, clinicaltrials.gov

NCT04314843

Phase 1, Terminated, 2020, 6 people, 19 Mar 2020, clinicaltrials.gov

NCT04150913

Collaborator, Phase 2, Completed, 2020, 15 people, 5 Nov 2019, clinicaltrials.gov

NCT03761056

Phase 2, Completed, 2019, 42 people, 3 Dec 2018, clinicaltrials.gov

NCT03391466

Phase 3, Completed, 2018, 359 people, 5 Jan 2018, clinicaltrials.gov

NCT03105336

Phase 2, Completed, 2017, 159 people, 7 Apr 2017, clinicaltrials.gov

NCT02926833

Phase 1/2, Completed, 2016, 37 people, 6 Oct 2016, clinicaltrials.gov

NCT02614066

Phase 1/2, Completed, 2016, 125 people, 25 Nov 2015, clinicaltrials.gov

NCT02601313

Phase 2, Completed, 2015, 105 people, 10 Nov 2015, clinicaltrials.gov

Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel

Employment, Consulting or advice, 8 Sept 2026, pubmed.ncbi.nlm.nih.gov